Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients

Journal of Nuclear Medicine

Volumn 47, Issue 7, 2006, Pages 1202-1208

  Pandit Taskar, Neeta ^a   Dauer, Lawrence T ^a   Montgomery, Leslie ^a   St Germain, Jean ^a   Zanzonico, Pat B ^a   Divgi, Chaitanya R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Absorbed dose; Breast cancer; Lymphoscintigraphy; Sentinel lymph node mapping

Indexed keywords

TECHNETIUM SULFUR COLLOID TC 99M; TECHNETIUM;

ADULT; ARTICLE; BREAST; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; FETUS; HEART; HUMAN; INJECTION; LIVER; LUNG; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; METHODOLOGY; OVARY; PHANTOM; PREGNANCY; PRIORITY JOURNAL; RADIATION DETECTION; RADIATION DOSE; SENTINEL LYMP NODE; STANDARD; THYMUS; TISSUE DISTRIBUTION; TUMOR BIOPSY; AGED; BREAST TUMOR; ENVIRONMENTAL EXPOSURE; IMAGE QUALITY; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PREGNANCY COMPLICATION; RADIOGRAPHY; RADIOMETRY; RETROSPECTIVE STUDY; SCINTISCANNING; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATERNAL EXPOSURE; MIDDLE AGED; PHANTOMS, IMAGING; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; RADIOMETRY; RADIONUCLIDE IMAGING; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM;

EID: 33747139438     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
2. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818-1822.
3. Yeung HW, Cody IH, Turlakow A, et al. Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols. J Nucl Med. 2001;42:420-423.
4. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-398.
5. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-339.
6. Goyal A, Newcombe RG, Mansel RE, et al. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. ALMANAC Trialists Group. Eur J Cancer. 2005;41:238-243.
7. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941-946.
8. Hill AD, Tran KN, Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999;229:528-535.
9. Hampton T. Surgeons "vote with their feet" for sentinel node biopsy for breast cancer staging. JAMA. 2003;290:3053-3054.
10. Stabin MG. OLINDA/EXM Personal Computer Code. Available at: http://www.doseinfo-radar.com/OLINDA.html. Accessed: May 24, 2006.
11. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310.
12. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: Society of Nuclear Medicine; 1991.
13. Stabin MG. OLINDA 1.0 Documentation Package. Nashville, TN: Vanderbilt University; 2004.
14. Stabin MG, Watson EE, Cristy M, et al. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. ORNL Report ORNL/TM-12907. Oak Ridge, TN: Oak Ridge National Laboratory; 1995.
15. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Trends in pregnancy rates for the United States, 197621997: an update. Natl Vital Stat Rep. 2001;49:1-9.
16. Moore HC, Foster RS Jr. Breast cancer and pregnancy. Semin Oncol. 2000;27:646-653.
17. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999;17:855-861.
18. Puckridge PJ, Saunders CM, Ives AD, Semmens JB. Breast cancer and pregnancy: a diagnostic and management dilemma. ANZ J Surg. 2003;73:500-503.
19. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003;138:91-98.
20. Schwartz GF, Giuliano AE, Veronesi U: Consensus Conference Committee. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 19222, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542-2551.
21. Keleher A, Wendt R 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10:492-495.
22. Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348-1351.
23. ICRP. 1990 Recommendations of the ICRP: International Commission on Radiological Protection. Publication 60. New York, NY: Pergamon Press; 1990.
24. Keshtgar MR, Waddington W, Lakhani SR, Ell PJ. The Sentinel Node in Surgical Oncology. Berlin, Germany: Springer-Verlag; 1999.
25. Strzelczyk I, Finlayson C. Sentinel node biopsy: ALARA and other considerations. Health Phys. 2004;86(2 suppl):S31-S34.
26. Zanzonico P. The intraoperative gamma probe: design, operation, and safety. In: Cody H, ed. Sentinel Node Biopsy. New York, NY: Taylor & Francis; 2001.
27. Paganelli G, Ferrari M, Cremonesi M, Gentilini O, Trifiro G. Optimised lymphoscintigraphy in pregnant patients with breast cancer is safe [reply letter]. Ann Oncol. 2005;16:674-675.
28. CDC. Prenatal radiation exposure: a fact sheet for physicians. Atlanta, GA: Centers for Disease Control and Prevention; 2003. Available at: http://www.bt.cdc.gov/radiation/prenatalphysician.asp. Accessed May 16, 2006.
29. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Teratology. 1999;59:182-204.
30. Timins JK. Radiation during pregnancy. N J Med. 2001;98:29-33.
31. ICRP. Pregnancy and medical radiation. International Commission on Radiological Protection. ICRP Publication no. 84. Ann ICRP. 2000;30(1):1-43.
32. NCRP. Limitation of Exposure to Ionizing Radiation. NCRP Report no. 116. Bethesda, MD: National Council on Radiation Protection and Measurements; 1993.
33. NCRP. Risk Estimates for Radiation Protection. NCRP Report no. 115. Bethesda, MD: National Council on Radiation Protection and Measurements; 1993.
34. Nickoloff EL, Brateman L. Proposition: a pregnant resident physician should be excused from training rotations such as angiography and nuclear medicine because of the potential exposure of the fetus. Med Phys. 1999;26:2517-2519.
35. NCRP. Considerations Regarding the Unintended Radiation Exposure of the Embryo, Fetus or Nursing Child: Commentary no. 9. Bethesda, MD: National Council on Radiation Protection and Measurements; 1994.
36. Richards KA, Stasko T. Dermatologic surgery and the pregnant patient. Dermatol Surg. 2002;28:248-256.
37. Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol. 2000;27:623-632.
38. ICRP. Summary of Current ICRP Report of Committee 3: Principles for Protection of Patient in Nuclear Medicine: International Commission on Radiological Protection; 1993.
39. NCRP. Exposure of the U.S. Population from Diagnostic Medical Radiation: Recommendations of the National Council on Radiation Protection and Measurements. NCRP Report no. 100. Bethesda, MD: National Council on Radiation Protection and Measurements; 1989.
40. NCRP. Sources and Magnitude of Occupational and Public Exposures from Nuclear Medicine Procedures: Recommendations of the National Council on Radiation Protection and Measurements. NCRP Report no. 124. Bethesda, MD: National Council on Radiation Protection and Measurements; 1996.